Sarah E. M. Herman - Concepedia

Author

Sarah E. M. Herman

National Heart Lung and Blood Institute ORCID

Also Known As

S E M Herman, S.E. Herman, Sarah E M Herman, Sarah E. M. Herman, Sarah E.M. Herman, Sarah EM Herman, Sarah Herman

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

National Heart Lung and Blood Institute National Institutes of Health National Institutes of Health Clinical Center National Cancer Institute Center for Cancer Research

About

Sarah E. M. Herman is an author at National Heart Lung and Blood Institute specializing in immunology, medicine, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	831
2	Immunology	7	7	831
3	Cell Biology	5	5	279
4	Pathology	3	3	567
5	Autoimmunity	1	1	15

Sarah E. M. Herman

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Sarah E. M. Herman, Amber Gordon, Erin Hertlein, Blood	2011	789
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial Mohammed Farooqui, Janet Valdez, Sabrina Martyr, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaTp53 AberrationsSingle-arm TrialMedicine	2014	365
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia Inhye E. Ahn, Chingiz Underbayev, Adam Albitar, Blood	2017	336
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer Gyamfi, Blood	2014	240
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib Clare Sun, Xin Tian, Yuh Shan Lee, Blood	2015	218
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients Betty Chang, Michelle Francesco, Martin F. M. de Rooij, Blood	2013	204
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Blood	2018	197
Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić, Clinical Cancer Research	2015	191
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study Sarah E. M. Herman, Carsten Utoft Niemann, Mahfooz Farooqui, Leukemia Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaIbrutinib-induced LymphocytosisMedicine	2014	187
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy Dan A. Landau, Clare Sun, Daniel Rosebrock, Nature Communications	2017	173

Page 1